BCD-121

Biocad · Phase 1 active Small molecule

At a glance

Generic name	BCD-121
Also known as	monoclonal bispecific antibody against human IL-17/ TNFa
Sponsor	Biocad
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BCD-121 CI brief — competitive landscape report
BCD-121 updates RSS · CI watch RSS
Biocad portfolio CI